Cure My Disease

Don't miss your cure!

 Log in / Sign up

Light-Based eye test could spot glaucoma risk early

NCT ID NCT06993597

Recruiting now Knowledge-focused Sponsor: University of Maryland, Baltimore Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 11, 2026 · Updated 3 times

Summary

This pilot study is testing whether a non-contact imaging technique called Brillouin microscopy can measure corneal stiffness in people with glaucoma. Researchers will compare these measurements between patients with high-tension glaucoma, normal-tension glaucoma, and healthy controls. The goal is to see if corneal stiffness can serve as a biomarker to predict glaucoma risk and progression. The study involves 60 participants and will also track changes after standard pressure-lowering eye drops.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Brillouin microscopy (non-contact imaging device)
What this could lead to
If successful, this could lead to a new way to assess glaucoma risk and track disease progression using a simple, non-invasive eye scan.
What could go wrong
This is a small, early-stage pilot study with only 60 participants. The measurements may not reliably predict glaucoma outcomes, and more research will be needed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLAUCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

corneal disorder glaucoma low tension glaucoma open-angle glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLAUCOMA

Contacts and locations

Locations

  • University of Maryland School of Medicine

    RECRUITING

    Baltimore, Maryland, 21201-1757, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.